Tritanium® Study in Japan
The Verification Study on the Early Fixation/ Stability of Tritanium Cup
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Ysuyuki Inatsugu
- Phone Number: +81-3-6894-8394
- Email: yasuyuki.inatsugu@stryker.com
Study Locations
-
-
Osaka
-
Izumisano, Osaka, Japan, 598-8577
- Recruiting
- Rinku General Medical Center
-
Contact:
- Phone Number: +81-72 - 469 - 3111
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient is a candidate for a primary Total Hip Arthroplasty (THA).
- Patient who has diagnosis of secondary osteoarthritis, avascular necrosis and rheumatoid arthritis.
- Patient whose age is 20 or over.
- Patient who signed an Institutional Review Board (IRB)-approved, study specific Informed Patient Consent Form.
- Patient who is willing and able to comply with postoperative scheduled evaluations.
Exclusion Criteria:
- Patient who has a bacterial infectious disease or has a high risk of a bacterial infection.
- Patient who requires revision surgery of a previously implanted total hip arthroplasty.
- Patient who is morbidly obese, defined as having a Body Mass Index (BMI) > 40.
- Patient who is or may be pregnant female.
- Patient who has neuromuscular or neurosensory deficiency, which limits ability to evaluate the safety and efficacy of the device.
- Patient with diagnosed systemic disease (i.e. Paget's disease, renal osteodystrophy), which limits ability to evaluate the safety and efficacy of the device.
- Patient who is immunologically suppressed or receiving chronic steroids, which limits ability to evaluate the safety and efficacy of the device.
- Patients who is judged ineligible with specific reason by primary doctor.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Tritanium® cup
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in implantation position(angle) of the cup
Time Frame: Baseline, intraoperative, 3 months, 6 months and 12 months
|
Baseline, intraoperative, 3 months, 6 months and 12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in Japanese Orthopaedic Association (JOA) score
Time Frame: Baseline, 3 months, 6months and 12 months
|
Baseline, 3 months, 6months and 12 months
|
|
Change in Quality of Life as assessed by Euro QOL 5 Dimension (EQ-5D)
Time Frame: Pre-operation, 3 months, 6months and 12 months
|
Pre-operation, 3 months, 6months and 12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Yasuyuki Inatsugu, Stryker Japan
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SJCR-OR-1505
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.